Intercept Pharmaceuticals, Inc.
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases such as primary biliary cirrhosis, also known as primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. For more information, please visit Intercept's website: www.interceptpharma.com.
DDW Tracks Microbiome in Gastrointestinal and Liver Diseases, Inflammatory Bowel Diseases, Liver Diseases and Transplantation, Esophageal Diseases, Stomach and Small Bowel Disorders, Colorectal Diseases, Functional GI and Motility Disorders, Pancreatic Diseases, Biliary Tract Diseases
Does your company only service US attendees? No